Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
AstraZeneca
UBS
Cantor Fitzgerald
Dow
Citi
Healthtrust
US Army
Daiichi Sankyo

Generated: October 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020692

« Back to Dashboard

NDA 020692 describes SEREVENT, which is a drug marketed by Glaxosmithkline and is included in two NDAs. It is available from two suppliers. Additional details are available on the SEREVENT profile page.

The generic ingredient in SEREVENT is salmeterol xinafoate. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the salmeterol xinafoate profile page.
Summary for 020692
Tradename:SEREVENT
Applicant:Glaxosmithkline
Ingredient:salmeterol xinafoate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020692
Mechanism of ActionAdrenergic beta2-Agonists
Medical Subject Heading (MeSH) Categories for 020692
Suppliers and Packaging for NDA: 020692
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SEREVENT salmeterol xinafoate POWDER;INHALATION 020692 NDA GlaxoSmithKline LLC 0173-0520 0173-0520-00 1 INHALER in 1 CARTON (0173-0520-00) > 28 POWDER, METERED in 1 INHALER
SEREVENT salmeterol xinafoate POWDER;INHALATION 020692 NDA GlaxoSmithKline LLC 0173-0521 0173-0521-00 1 INHALER in 1 CARTON (0173-0521-00) > 60 POWDER, METERED in 1 INHALER

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrengthEQ 0.05MG BASE/INH
Approval Date:Sep 19, 1997TE:RLD:Yes

Expired US Patents for NDA 020692

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Cerilliant
AstraZeneca
Johnson and Johnson
McKinsey
Mallinckrodt
Chinese Patent Office
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.